Urbánek Karel, Kolár Milan, Strojil Jan, Koukalová Dagmar, Cekanová Luboslava, Hejnar Petr
Department of Pharmacology, Faculty of Medicine, Palacký University, Olomouc, Czech Republic.
Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):741-5. doi: 10.1002/pds.1110.
The aim of this study was to evaluate the dependence of Escherichia coli resistance to fluoroquinolones on their use in the outpatients and inpatients in the Olomouc region of the Czech Republic.
Data on inpatient antibiotic use were obtained from the database of the Department of Pharmacology and expressed as defined daily dose per 100 bed-days (DBD). Data on outpatient prescriptions were obtained from the database of General Health Insurance Company and expressed in defined daily doses per 1000 clients per day (DID). Escherichia coli strains were isolated from samples of urine of both community and hospitalized patients suffering from acute bacterial urinary tract infection, examined using aerobic cultivation, and determined by standard biochemical procedures.
The utilization of fluoroquinolones in inpatients has significantly (p < 0.01) increased from 2.52 DBD in 1997 to 4.29 DBD in 2002. In outpatients, fluoroquinolone utilization has also increased significantly from 0.14 to 0.95 DID (p < 0.01). In the same period, 9192 E. coli strains were isolated from inpatients and outpatients suffering by urinary tract infections and tested for the susceptibility to fluoroquinolones. Resistance increased significantly (p < 0.01) both in the hospital (from 2 to 9%) and in the community (from 1 to 10%). The development of E. coli resistance to fluoroquinolones correlates significantly with their utilization both in the hospital (r = 0.944, p = 0.005) and in the community (r = 0.859, p = 0.029).
Results of this study shows the impact of fluoroquinolone utilization on E. coli resistance and support the need of controlled use of these effective antibiotics.
本研究旨在评估捷克共和国奥洛穆茨地区门诊和住院患者中,大肠杆菌对氟喹诺酮类药物耐药性与其使用之间的相关性。
住院患者抗生素使用数据来自药理学系数据库,以每100床日限定日剂量(DBD)表示。门诊处方数据来自国家健康保险公司数据库,以每天每1000名患者的限定日剂量(DID)表示。从患有急性细菌性尿路感染的社区和住院患者的尿液样本中分离出大肠杆菌菌株,采用需氧培养法进行检测,并通过标准生化程序进行鉴定。
住院患者中氟喹诺酮类药物的使用量从1997年的2.52 DBD显著增加至2002年的4.29 DBD(p < 0.01)。门诊患者中,氟喹诺酮类药物的使用量也从0.14显著增加至0.95 DID(p < 0.01)。同期,从患有尿路感染的住院和门诊患者中分离出9192株大肠杆菌菌株,并检测其对氟喹诺酮类药物的敏感性。医院内(从2%增至9%)和社区(从1%增至10%)的耐药率均显著上升(p < 0.01)。大肠杆菌对氟喹诺酮类药物的耐药性发展与医院(r = 0.944,p = 0.005)和社区(r = 0.859,p = 0.029)中该类药物的使用均显著相关。
本研究结果显示了氟喹诺酮类药物使用对大肠杆菌耐药性的影响,并支持对这些有效抗生素进行控制使用的必要性。